Why CG Oncology’s latest earnings matter for shareholders

CG Oncology (CGON) reported first quarter revenue of US$1.08 million and a net loss of US$60.2 million, giving investors fresh numbers to reassess the stock’s risk and potential reward profile.

CG Oncology’s share price has moved to US$69.18, with a 1-day share price return of 1.72% and a 7-day return of 3.66%. The 90-day share price return of 37.37% and year-to-date share price return of 65.54% sit alongside a 1-year total shareholder return of 186.70%, reflecting recent share price momentum as investors weigh higher revenue against wider losses and upcoming conference appearances.

If earnings volatility and clinical milestones have your attention, this can be a good moment to compare other listed healthcare AI opportunities through our curated screener of 35 healthcare AI stocks

So with CG Oncology trading at US$69.18, sitting below the average analyst price target of US$87.86 and carrying a value score of 4, is this a case of mispricing or is the market already accounting for future growth?

Preferred price to book of 8.1x: Is it justified?

CG Oncology trades at a P/B of 8.1x, and that sits well above the US Biotechs industry average of 2.5x even after the recent share price moves around earnings.

P/B compares the market value of the company to its book value. For a late stage clinical biopharmaceutical business like CG Oncology this mainly reflects cash, trial assets, and other net assets on the balance sheet rather than established recurring earnings.

Given CG Oncology is currently unprofitable and does not yet have meaningful revenue at $4 million, an 8.1x P/B implies the market is placing a substantial premium on its bladder cancer pipeline, future cash flow potential and clinical progress relative to what is on the balance sheet today.

Compared with the broader US Biotechs industry P/B of 2.5x, CG Oncology’s higher multiple shows investors are already pricing in a stronger outcome than the sector average. Still, our DCF model suggests the stock is trading at a 79.5% discount to an estimated future cash flow value of $338.28, which is a very large gap to the current $69.18 share price and frames an alternative view of value compared with simple balance sheet multiples.

Result: Price-to-book of 8.1x (OVERVALUED)

However, the US$160.995 million net loss and heavy reliance on a single late stage bladder cancer asset mean that any trial setback or funding pressure could quickly challenge today’s valuation.

DCF view suggests a very different story

While the 8.1x P/B points to an expensive stock versus the wider US Biotechs industry, the SWS DCF model points the other way. It indicates that CG Oncology is trading at a 79.5% discount to an estimated future cash flow value of $338.28 per share. Which signal do you treat as more important?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CG Oncology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Conflicted by the mix of potential and risk in CG Oncology’s story today? Use the full dataset to stress test your own thesis with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If CG Oncology has sharpened your thinking, do not stop here. Broaden your watchlist with stocks that match different risk, income, and value profiles.

• Target potential value opportunities by scanning 51 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
• Strengthen your income focus by reviewing 12 dividend fortresses that offer higher yields with a focus on stability.
• Prioritize resilience by checking 72 resilient stocks with low risk scores that score well on financial and risk metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.